Biotech News
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
ATLAS phase II/III trial in VEXAS underway, advancing momelotinib’s broader development programme.
Biotech News
ATLAS phase II/III trial in VEXAS underway, advancing momelotinib’s broader development programme.
No closely related headlines were available from the latest feed snapshot.
GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.